Embodiments disclosed herein relate scaffolds containing fluoridated apatites sintered at a temperature of at least 950° C. and with at least one integration aid to increase integration of the scaffold in a patient, as well as methods of making and using the same.

This disclosure describes decellularized, biologically-engineered tubular grafts and methods of making and using such decellularized, biologically-engineered tubular grafts.

Methods for making surgical implants (or grafts) for the repair of bone defects, and more particularly, surgical implants that include demineralized bone fibers, are disclosed. Also disclosed are methods for increasing the wettability and ensuring uniform density of such implants. The surgical implants have a wettability time of less than 5 minutes and a residual moisture content of less than 6% by weight, and they remain cohesive and retain their shape upon complete rehydration.

The present invention is directed to a method for producing a condensed phase of a silk fusion protein, the method comprising the steps of preparing a solution of a silk fusion protein in an aqueous medium and concentrating the silk fusion protein in the aqueous medium, wherein the fusion protein is isolated from a recombinant production host and comprises a silk-like protein sequence and two separate non-silk terminal module sequences, such as cellulose binding modules, SpyCatcher domains, tenth type III module of Fibronectin, gamma-crystallin D, flanking the silk-like protein sequence; wherein the method is performed so that the silk fusion protein is not precipitated and subsequently dissolved to the aqueous medium. The present invention is also directed to using such fusion proteins as adhesives.

A tissue graft for soft tissue repair or reconstruction comprising a sheet of a biopolymer-based matrix having a plurality of small perforations and a plurality of large perforations. The small perforations are sized to facilitate clotting and granulation tissue development within the perforations which, in turn, facilitates revascularization and cell repopulation in the patient. The large perforations are sized to reduce the occurrence of clotting and granulation tissue development within the perforations so that extravascular tissue fluids accumulating at the implant site can drain through the tissue graft. The large perforations enhance mammal tissue anchoring by permitting mammal tissue to compress into the perforations increasing mammal tissue contact area.

The present disclosure provides tissue products produced from adipose tissues, as well as methods for producing such tissue products. The tissue products can include acellular tissue matrices for treatment of a breast.

The present disclosure provides tissue products produced from extracellular tissue matrices. The tissue products can include acellular extracellular matrices that have been treated in select areas to increase the compressive modulus of the matrix in the selected area while maintaining the ability to support cell growth and tissue regeneration. In addition, the tissue products can include collagen-containing materials that support tissue ingrowth along with a framework of collagenous or polymeric materials such that the combination has a desired compressive or tensile modulus and/or strength while maintaining the ability to support cell growth and tissue regeneration.

The kidney regeneration accelerator that contains a component obtained by decellularizing a mammalian organ. The production method for a kidney regeneration accelerator that involves decellularizing a mammalian organ to obtain a component that includes an extracellular matrix, freeze drying and then pulverizing the component to obtain a powder, and performing a sterilization treatment on the powder. A pharmaceutical composition for use in treating kidney disease that contains a component obtained by decellularizing a mammalian organ. A treatment method for kidney disease that involves applying a pharmaceutical composition that contains a component obtained by decellularizing a mammalian organ to a site to be treated of the kidney of a human or animal kidney disease patient.

The chemically cross-linked hydrogel is a hydrogel formed by reaction of silk with a crosslinking agent, and the crosslinking agent is a diglycidyl ether crosslinking agent. The hydrogel is obtained by dissolving silk fibers in a lithium bromide solution and crosslinking through the crosslinking agent. The hydrogel has good elasticity, and can recover more than 90% of its volume/height after being compressed for 100 cycles with a compressive deformation of 20%. The silk is very stable in matrix structure and mechanical properties. After incubation in PBS at 37° C. for 30 days, the content of β-sheets in the secondary structure elements of the silk is less than or equal to 40%, and its compressive modulus is less than or equal to 100% (with a compressive deformation of 20%). The hydrogel has good biocompatibility and adjustable biodegradability, and can be used for repairing or filling tissues in subjects.

Disclosed herein are hydrogel devices and methods of making an use thereof. The devices can comprise: a continuous hydrogel matrix; a first chamber in the hydrogel matrix; and a second chamber in the hydrogel matrix; wherein the first chamber and the second chamber are each independently perfusable; wherein the first chamber is fluidly independent from the second chamber; wherein the first chamber is configured to be at least partially filled with adipose tissue; wherein the second chamber is configured to be at least partially filled with an oxygenated fluid; wherein the first chamber is defined by a first border; wherein the second chamber is defined by a second border; and wherein the first chamber and the second chamber are spaced apart from each other by an average distance of from 50 micrometers (microns, μm) to 800 μm as measured from the first border to the second border.